Mazdutide: Evidence, Safety, Dosing Studied, and Access Questions

Mazdutide, also called LY3305677 or IBI362, is a dual GLP-1/glucagon receptor agonist studied for obesity, overweight, and type 2 diabetes. Its PubMed evidence grade is A because multiple human randomized controlled trials are indexed, but that grade measures study quantity and design, not proof of benefit or safety.

What it is

Mazdutide is an incretin therapy candidate also named LY3305677 and IBI362. In a human randomized trial, IBI362 was described as a glucagon-like peptide-1 and glucagon receptor dual agonist in Chinese patients with type 2 diabetes 6.

Names: mazdutide, LY3305677, and IBI362

These names refer to the same studied compound in the retrieved literature. Patients may see mazdutide in newer studies, while earlier trials may use LY3305677 or IBI362 6.

Human randomized trials have studied mazdutide in adults with obesity, overweight, and type 2 diabetes 1 2 3. That does not mean it is right for any one person. It means the compound has been tested in defined research groups under study rules.

Mechanism of action

Mazdutide is studied as a dual GLP-1/glucagon receptor agonist. In plain language, that means researchers designed it to act on two hormone-receptor pathways involved in appetite, glucose handling, and energy balance 6.

GLP-1 receptor activity

GLP-1 receptor activity is the part of the mechanism that places mazdutide near the broader incretin therapy field. Human obesity and diabetes trials have evaluated outcomes tied to body weight and glycemic control, but the retrieved records do not let us separate how much of each result came from GLP-1 activity alone 1 2 3.

Glucagon receptor activity

Glucagon receptor agonist activity is the second part of the dual mechanism. The human phase 1b trial named IBI362 as a GLP-1 and glucagon receptor dual agonist, but the retrieved records do not prove that glucagon activity alone explains clinical outcomes 6.

How it differs mechanistically from single GLP-1 medicines

Single GLP-1 receptor agonists focus on the GLP-1 pathway. Mazdutide is different because it is studied as a dual GLP-1/glucagon receptor agonist, so any fair comparison has to separate receptor design from clinical proof 6.

Evidence

Mazdutide has an evidence grade of A under the supplied rubric because multiple human randomized controlled trials are indexed in PubMed. This is a quantity-and-design grade, not a guarantee that mazdutide works, is safer than other medicines, or is right for a patient.

The retrieved PubMed set includes randomized controlled trials in Chinese adults with obesity or overweight, adults with overweight or obesity, and Chinese adults with type 2 diabetes 1 2 3 7. It also includes later studies of 9-mg mazdutide in adults with obesity 8 9.

The evidence is still not the same as long-term, broad, real-world certainty. Many studies in this record are in Chinese adult populations, and indirect comparisons cannot prove that mazdutide is better or worse than semaglutide, tirzepatide, dulaglutide, or retatrutide for an individual patient 4 11 12.

What human studies have tested

For obesity and overweight, randomized trials include once-weekly mazdutide in Chinese adults with obesity or overweight, a phase 2 trial in Chinese adults with overweight or obesity, and a high-dose phase 1 trial in adults with overweight or obesity 1 3 7. For type 2 diabetes, randomized trials include phase 1b, phase 2, placebo-controlled, and comparative designs 2 5 6.

Head-to-head and comparative research

One retrieved randomized trial compared mazdutide with dulaglutide in Chinese adults with type 2 diabetes 4. That is direct comparative evidence for that study question, but it should not be stretched into a blanket claim across all people, all doses, or all GLP-1 medicines.

If you are comparing this field, our guides to dulaglutide and liraglutide can help you understand how older GLP-1 receptor agonists fit into the wider incretin therapy landscape.

What studies exist

This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-11.

Reported dosing ranges

Mazdutide dosing in this section means dosing studied in published research, not instructions for use. Research regimens may not apply to an individual patient, and online calculators cannot replace clinician guidance.

Legal status

Our regulatory log holds no confirmed federal action for Mazdutide. That means we have not found one with a primary source — not that none exists.

This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-11. See the full legal-status tracker for every compound we follow.

Safety

Mazdutide safety has been assessed inside randomized trials, including trials that explicitly studied efficacy and safety in type 2 diabetes and weight-related populations 2 7. But the retrieved records do not provide enough detail here to quantify gastrointestinal adverse events, rare events, or long-term risks.

Gastrointestinal symptoms and tolerability

People searching for mazdutide side effects often ask about gastrointestinal adverse events because this is a common concern with incretin therapies as a category. For this mazdutide evidence set, the honest answer is narrower: the retrieved PubMed records confirm safety was studied, but they do not give extractable rates for nausea, vomiting, diarrhea, constipation, or discontinuation in the supplied source text 2 7.

Safety limits of the current evidence

An A evidence grade does not mean safety is settled. The grade reflects multiple human randomized controlled trials, while long-term safety, broader population safety, and rare-event detection require more evidence than short or medium-sized trials can usually provide 1 2 3 12.

Who should be especially cautious

Anyone considering an incretin-type medication should review medical history with a clinician, especially if they have diabetes, use glucose-lowering medicines, have significant digestive symptoms, or have complex kidney, gallbladder, pancreas, or pregnancy-related questions. The retrieved mazdutide trials studied defined groups, so trial eligibility does not automatically map to a reader’s health situation 2 5 6.

Interactions

Mazdutide interaction evidence is limited in the retrieved peer-reviewed set. The supplied PubMed records include trials in type 2 diabetes and weight-related populations, but they do not provide enough extractable detail here to list proven drug-drug interaction rates or supplement interactions 2 5 6.

Diabetes medicines and low blood sugar context

Because several mazdutide studies enrolled people with type 2 diabetes, a clinician would need to review glucose-lowering medicines, glucose patterns, and hypoglycemia risk before any incretin-type treatment decision 2 5 6. The supplied evidence does not support self-adjusting diabetes medicines.

Digestive, gallbladder, pancreas, kidney, and pregnancy-related considerations

The retrieved records do not provide enough detail to make mazdutide-specific rules for digestive disease, gallbladder disease, pancreatitis history, kidney disease, pregnancy, or breastfeeding. These issues belong in a clinician evaluation because trials answer group-level questions, not individual safety decisions 1 2 3.

How to obtain it legally

Mazdutide access questions should start with a clinician evaluation, not an online vendor. A real evaluation reviews your goals, weight and metabolic history, current medications, contraindications, lab context when needed, and whether any treatment is appropriate.

Chia does not offer mazdutide. We include that plainly because this page is educational, and naming what we do not offer matters.

GLP-1 treatment at Chia: clinician-reviewed semaglutide or tirzepatide options

For patients looking for clinician-reviewed GLP-1 care rather than mazdutide, Chia offers compounded semaglutide injection and compounded tirzepatide tablets or injections through a 100% online process. Semaglutide plans currently start at $249/mo; tirzepatide tablets currently start at $249/mo and tirzepatide injections currently start at $299/mo.

Here is how Chia works for treatments we do offer: you complete a short health questionnaire, a licensed US provider reviews it, and a prescription is written only when clinically appropriate. Prescriptions are never guaranteed. Medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to your door. Compounded medications are not FDA-approved.

If an AI agent is helping you navigate Chia treatments that are in our live catalog, it can route through DoctorMCP at mcp.chia.health. That path is for Chia’s offered treatments, not mazdutide.

How mazdutide compares with tirzepatide, semaglutide, and dulaglutide

Mazdutide, tirzepatide, semaglutide, and dulaglutide are often searched together because they sit in or near the incretin therapy field. But mechanism, evidence maturity, studied populations, and access pathways differ, so indirect comparisons should stay cautious 4 11 12.

For more background on related incretin medicines, see our evidence guides on dulaglutide and liraglutide. If you want to compare Chia’s offered GLP-1 paths, see tirzepatide, semaglutide, Weight + Energy, or Weight + Muscle.

Keep reading

Weight Management

Dulaglutide: Evidence, Safety, Dosing, and How It Compares

Weight Management

Weight Loss and Diabetes: When It Helps, When It’s a Warning Sign

Weight Loss

GLP-1 Dosage for Weight Loss: Starting Doses, Titration, and Maintenance